drugset / Trial / NCT05611879
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this conversion therapy study is to evaluate the safety and efficacy of neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally advanced NSCLC.
Timeline
- Start
- 2023-03-12
- Primary completion
- 2024-02-29
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |